Vitruvias Therapeutics, LLC and Sunny Pharmtech Inc. announced that they have formed a strategic partnership to co-develop a varied portfolio of generic drugs. The agreement will leverage the research, development, and distribution capabilities of each company to quickly and efficiently develop and commercialize generic products in markets that currently exceed $400 mil. Each company will have a 50% stake in product portfolio, and the first ANDA will be tentatively filed in the fourth quarter of 2015.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.1 TWD | +1.50% | +1.50% | -21.34% |
18/04 | Sunny Pharmtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Sunny Pharmtech Inc.(TPEX:6676) added to S&P Global BMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-21.34% | 12Cr | |
+45.91% | 75TCr | |
+41.50% | 63TCr | |
-6.07% | 35TCr | |
+20.08% | 33TCr | |
+9.11% | 30TCr | |
+18.79% | 25TCr | |
+12.16% | 22TCr | |
-0.49% | 22TCr | |
+6.65% | 16TCr |
- Stock Market
- Equities
- 6676 Stock
- News Sunny Pharmtech Inc.
- Vitruvias Therapeutics, LLC and Sunny Pharmtech Inc. Form Partnership to Co-Develop Several High Value Generic Drugs